SCHEMBL4837467

SCHEMBL4837467

CC(C)S(=O)(=O)n1c(N)nc2ccc(C(=O)C(=O)c3ccccc3)cc21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 1/20 0.74
MAPK14 Q16539 18/20 0.54
CYP3A4 P08684 6/20 0.54
ABL1 P00519 1/20 0.45
EGFR P00533 1/20 0.45
ERBB2 P04626 1/20 0.45
FYN P06241 1/20 0.45
PIM1 P11309 1/20 0.45
FGFR1 P11362 1/20 0.45
MAPK1 P28482 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
MAPK8 P45983 1/20 0.45
MAPK9 P45984 1/20 0.45
CSNK1D P48730 1/20 0.45
LIMK1 P53667 1/20 0.45
DYRK1A Q13627 1/20 0.45
CDC42BPA Q5VT25 1/20 0.45
AURKB Q96GD4 1/20 0.45
PRKD2 Q9BZL6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10906292 0.91 PI4KB (0.74) PI4KBMAPK14CYP3A4ABL1EGFR
SCHEMBL4837701 0.89 PI4KB (0.60) PI4KBMAPK14CYP3A4ABL1EGFR
SCHEMBL11149101 0.88 PI4KB (0.71) PI4KBMAPK14CYP3A4ABL1EGFR
SCHEMBL11148839 0.87 PI4KB (0.70) PI4KBMAPK14CYP3A4
SCHEMBL11073939 0.87 PI4KB (0.72) PI4KBMAPK14CYP3A4
SCHEMBL11145549 0.86 PI4KB (0.69) PI4KBMAPK14CYP3A4ABL1EGFR
SCHEMBL11145881 0.86 PI4KB (0.69) PI4KBMAPK14CYP3A4ABL1EGFR
SCHEMBL11145546 0.86 PI4KB (0.69) PI4KBMAPK14CYP3A4ABL1EGFR
SCHEMBL11160244 0.86 PI4KB (0.69) PI4KBMAPK14CYP3A4ABL1EGFR
SCHEMBL11150109 0.86 PI4KB (0.69) PI4KBMAPK14CYP3A4ABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320995-B2 Benzimidazoles and benzothiazoles as inhibitors of map kinase ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1554272-B1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE LILLY CO ELI (US) 2006-10-25 EP disclosed
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase EIL LILLY AND COMPANY (US) 2005-12-08 US disclosed
EP-1554272-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2005-07-20 EP disclosed
WO-2004014900-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase MAP3K8, MAPK8, MAPK1 PI4KB 282/4885MAPK14 10/4885CYP3A4 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.